林克制药公司的LNK01004显示,在治疗中度至evere eczema和尽量减少副作用方面,取得了显著成果。 Lynk Pharmaceuticals' LNK01004 shows strong results in treating moderate-to-severe eczema with minimal side effects.

林克制药公司报告了对局部JAK抑制剂LNK01004的II期试验结果,该药用于治疗中度至重度的亚托皮炎. Lynk Pharmaceuticals reports positive Phase II trial results for LNK01004, a topical JAK inhibitor, in treating moderate-to-severe atopic dermatitis. 在对75名成年人进行的一项研究中,8周后,对0.3%和1.0%的剂量的反应率明显高于安慰剂,尤其是在皮肤参与程度较高的患者中。 In a study of 75 adults, both 0.3% and 1.0% doses showed significantly higher response rates than placebo after eight weeks, especially in patients with greater skin involvement. 该药物显示系统接触率低,安全情况良好,没有产生严重的副作用。 The drug demonstrated low systemic exposure and a favorable safety profile with no serious side effects. 该公司说,LNK01004可以提供安全、有效的治疗,而不进行系统的免疫抑制。 The company says LNK01004 may offer a safe, effective treatment without systemic immunosuppression.